Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 May 31:17:e00566.
doi: 10.1016/j.idcr.2019.e00566. eCollection 2019.

Disseminated cryptococcal infection in a patient with treatment-naïve chronic lymphocytic leukemia (CLL)

Affiliations
Case Reports

Disseminated cryptococcal infection in a patient with treatment-naïve chronic lymphocytic leukemia (CLL)

Adam Suleman et al. IDCases. .

Abstract

We report a case of disseminated cryptococcosis in a treatment-naïve chronic lymphocytic leukemia (CLL) patient. A 60-year-old man presented with a two-week history of intermittent fevers, frontal headaches, night sweats, weight loss and multiple pink papules on hands and face. Cryptococcemia was found by blood culture unexpectedly. Further investigation confirmed cryptococcal meningitis and skin disease. He responded to two week amphotericin B and flucytosine followed by four-week amphotericin B and fluconazole, three-month high dose fluconazole (800 mg/day), and maintenance fluconazole (400 mg/day) thereafter. CSF pleocytosis persisted until day 203 while cryptococcal antigen in the CSF persisted at day 334 of treatment.

Keywords: Chronic lymphocytic leukemia; Cryptococcus.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
A. Rash on the patient’s hand upon initial presentation. B. Section of skin biopsy with hematoxylin and eosin stain, original magnification 20 × . C. Photomicrograph of the skin biopsy showing large numbers of yeast forms surrounded by a clear space, typical of the thick capsule of Cryptococcus. (Mucicarmine, magnification 63x, courtesy of Dr. Bruce Burns).
Fig. 2
Fig. 2
Cerebrospinal fluid A. Yeast cells on day 14 of treatment and B. Degenerating yeast cells on day 334 of treatment. (May-Grünwald-Giemsa, original magnification 100x oil immersion.).

Similar articles

Cited by

References

    1. Warkentien T., Crum-Cianflone N.F. An update on cryptococcosis among HIV-Infected persons. Int J STD AIDS. 2010;21:679–684. - PMC - PubMed
    1. Rajasingham R., Smith R.M., Park B.J., Jarvis J.N., Govender N.P., Chiller T.M. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17:873–881. - PMC - PubMed
    1. Park B.J., Wannemuehler K.A., Marston B.J., Govender N., Pappas P.G., Chiller T.M. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23:525. - PubMed
    1. Lortholary O., Poizat G., Zeller V., Neuville S., Boibieux A., Alvarez M. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS Lond Engl. 2006;20:2183–2191. - PubMed
    1. Liao T.-L., Chen Y.-M., Chen D.-Y. Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2016;22:815. e1-815.e3. - PubMed

Publication types

LinkOut - more resources